Trending NewsTrending NewsNASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis $123.45 +0.10 (+0.08%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$123.43 -0.02 (-0.02%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvalent Stock (NASDAQ:NUVL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvalent alerts:Sign Up Key Stats Today's Range$123.15▼$123.5750-Day Range$88.49▼$123.4552-Week Range$71.13▼$123.62Volume6.58 million shsAverage Volume3.67 million shsMarket Capitalization$9.75 billionP/E RatioN/ADividend YieldN/APrice Target$131.15Consensus RatingHold Company Overview Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets. Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations. These assets are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with early data demonstrating favorable safety profiles and preliminary signs of clinical activity in patients with RET-driven and KRAS-mutant solid tumors. In addition to these core programs, Nuvalent continues to leverage its structure-based approach to advance discovery efforts and expand its portfolio into other oncogenic targets. The company conducts its operations primarily in North America, supported by strategic collaborations and investigator-led studies in international research centers. Under the leadership of President and Chief Executive Officer Bill Haney, Nuvalent has assembled a management team with extensive experience in oncology drug development, regulatory affairs and commercial planning. The organization remains committed to translating cutting-edge science into precision medicines that address unmet needs in cancer therapy.AI Generated. May Contain Errors. Read More Nuvalent Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreNUVL MarketRank™: Nuvalent scored higher than 36% of companies evaluated by MarketBeat, and ranked 709th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingHold Consensus RatingNuvalent has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 5 buy ratings, 14 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Nuvalent is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageNuvalent has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nuvalent's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nuvalent are expected to grow in the coming year, from ($5.74) to ($3.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -20.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -20.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 7.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvalent's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.99% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 9.04.Change versus previous monthShort interest in Nuvalent has recently increased by 6.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.12 News SentimentNuvalent has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 54 news articles for Nuvalent this week, compared to 6 articles on an average week.Search Interest2 people have searched for NUVL on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,612,264.00 in company stock.Percentage Held by Insiders5.02% of the stock of Nuvalent is held by insiders.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvalent's insider trading history. Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NUVL Stock News HeadlinesTop Medical Stocks To Consider - June 9th46 minutes ago | americanbankingnews.comBest Pharmaceutical Stocks To Consider - June 9th1 hour ago | americanbankingnews.comPlease open before June 12!The SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.June 12 at 1:00 AM | InvestPub (Ad)Promising Mid Cap Stocks To Follow Now - June 9th1 hour ago | americanbankingnews.comPatent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionGSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.June 11 at 10:35 AM | marketbeat.comNuvalent (NASDAQ:NUVL) CEO James Richard Porter Sells 30,000 SharesJune 11 at 6:59 AM | insidertrades.comNuvalent (NASDAQ:NUVL) CFO Sells $1,128,026.70 in StockJune 4, 2026 | insidertrades.comDeborah Ann Miller Sells 5,500 Shares of Nuvalent (NASDAQ:NUVL) StockJune 2, 2026 | insidertrades.comSee More Headlines NUVL Stock Analysis - Frequently Asked Questions How have NUVL shares performed this year? Nuvalent's stock was trading at $100.59 on January 1st, 2026. Since then, NUVL shares have increased by 22.7% and is now trading at $123.45. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by $0.04. When did Nuvalent IPO? Nuvalent (NUVL) raised $180 million in an initial public offering (IPO) on Wednesday, July 28th 2021. The company issued 10,612,500 shares at a price of $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Nuvalent's top institutional shareholders include Perceptive Advisors LLC (2.00%), Janus Henderson Group PLC (1.57%), Commodore Capital LP (1.06%) and Pictet Asset Management Holding SA (0.52%). Insiders that own company stock include Andrew A F Hack, Matthew Shair, James Richard Porter, Alexandra Balcom, Henry E Pelish, Deborah Ann Miller, Christopher Durant Turner, Darlene Noci and Emily Conley. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvalent own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvalent investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/07/2026Today6/12/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 As of 3 days ago, NUVL's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NUVL CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees40Year Founded2017Price Target and Rating Average Price Target for Nuvalent$131.15 High Price Target$189.00 Low Price Target$105.00 Potential Upside/Downside+6.2%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($6.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$425.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.11% Return on Assets-35.43% Debt Debt-to-Equity RatioN/A Current Ratio16.14 Quick Ratio16.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.95 per share Price / Book7.74Miscellaneous Outstanding Shares79,000,000Free Float75,032,000Market Cap$9.75 billion OptionableOptionable Beta1.15 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:NUVL) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersIs your wealth prepared for “America’s Most Dangerous Man”? (Read before June 16)60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...Chaikin Analytics | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredJon Najarian: “Make this move now that SPCX is trading”SpaceX is now publicly trading under the ticker SPCX - but Hall of Fame Trader Jon Najarian says the real oppo...Banyan Hill Publishing | SponsoredTrump’s Government Went 4 for 4 Last Year … Who’s Next?Last year, the U.S. government bought shares in four companies - and all four surged afterward. MP Materials c...Weiss Ratings | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
